Angiotensin II receptor blockers for the treatment of hypertension
Author:
- 1 November 2001
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 2 (11) , 1795-1804
Abstract
The rising incidence of stroke, congestive heart failure (CHF) and end stage renal disease (ESRD) has signalled a need to increase awareness, treatment and control of hypertension. There continues to be a need for effective antihypertensive medications since hypertension is a major precursor to various forms of cardiovascular disease. The renin-angiotensin (AT) aldosterone system (RAAS) is a key component to the development of hypertension and can be one target of drug therapy. Angotensin II (ATII) receptor blockers (ARBs) are the most recent class of agents available to treat hypertension, which work by by inhibiting ATII at the receptor level. Currently, national consensus guidelines recommend that ARBs should be reserved for hypertensive patients who cannot tolerate angiotensin converting enzyme (ACE) inhibitors (ACEIs). ARBs, however, are moving to the forefront of therapy with a promising role in the area of renoprotection and CHF. Recent trials such as the The Renoprotective Effect of the Angiotensi...Keywords
This publication has 22 references indexed in Scilit:
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- EprosartanDrugs, 2000
- Safety of losartan in hypertensive patients with thiazide-induced hyperuricemiaKidney International, 1999
- ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertensionJournal of Human Hypertension, 1999
- TelmisartanDrugs, 1998
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)The Lancet, 1997
- Angiotensin Receptors and Their AntagonistsNew England Journal of Medicine, 1996
- Angioedema Induced by the Angiotensin II Blocker LosartanNew England Journal of Medicine, 1995
- Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with PlaceboNew England Journal of Medicine, 1993